Viatris Inc.

MArch 26, 2025

Please complete the form below to contact Kaplan Fox regarding the Viatris Investigation:

Join a Case
Are you a current or former employee of the company mentioned having traded above?

Principle Contacts

Pamela Mayer

PMayer@kaplanfox.com

Laurence D. King

LKing@kaplanfox.com
Viatris Inc.

Kaplan Fox & Kilsheimer LLP is Investigating Viatris Inc. (VTRS) for Potential Securities Law Violations

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS).

CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION

If you are a Viatris investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003.

On February 27, 2024, Viatris issued a press release reporting its fourth quarter and full year 2024 financial results and providing an update concerning its Indore, India facility.  The press release states that “[f]ollowing an inspection of Viatris’ oral finished dose manufacturing facility in Indore, India in June 2024 the Company received a warning letter and import alert from the U.S. Food and Drug Administration (FDA) in December 2024” and that [t]he import alert affects 11 actively distributed products. . . .”  Further, the press release states that “[t]he Company currently estimates the negative impact on 2025 total revenues to be approximately $500 million and to 2025 adjusted EBITDA to be approximately $385 million.”

Additionally, Viatris advised that following the FDA’s June 2024 inspection, “[t]he Company immediately implemented a comprehensive remediation plan” and that it was “more than halfway through its remediation efforts and expects to be completed in a few months at which time the Company anticipates requesting FDA to conduct a reinspection of the facility.”  However, the Company said that while “product continues to be shipped from the Indore facility to markets outside the U.S., the Company currently anticipates some impact in other markets, including to parts of its ARV business in Emerging Markets and to select generic products in Europe.”

Following this news, the price of Viatris stock fell $1.71 per share, over 15%, to close at $9.53 per share on February 27, 2025.

WHY CONTACT KAPLAN FOX

Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.  With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.  Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients.  For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

If you have any questions about this investigation, please contact:

CONTACT:

Pamela A. Mayer
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(646) 315-9003
pmayer@kaplanfox.com

Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com

The submission of this form does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client. Any information you submit will be maintained as confidential. If Kaplan Fox, in its sole discretion, believes that you might be an appropriate client, Kaplan Fox will contact you to discuss the matter and whether to establish an attorney client relationship. By signing this form you are authorizing us to contact you regarding this case and/or future cases.

Connect with Kaplan Fox.

Receive a complimentary case review now.

Contact Us